7
Participants
Start Date
March 15, 2022
Primary Completion Date
May 1, 2024
Study Completion Date
August 1, 2024
dulaglutide injection
All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
Vanderbilt University Medical Center, Nashville
VA Tennessee Valley Health Care System
FED
Vanderbilt University Medical Center
OTHER